TrialStat Announces New Pricing Program for ClinicalAnalytics 4.0

Share Article

Increased Flexibility Delivers More Control over Study Cost and Risk

One of our core values has always been industry leading project deployments and we can now augment this with equally timely proposals.

TrialStat Corporation, the industry's first clinical data solutions on demand company, today announced enhanced pricing options for customers using its ClinicalAnalytics 4.0 EDC solution. The changes are designed to address the needs of TrialStat's growing portfolio of clients running larger, late-phase multi-year studies.

In addition to the new pricing program, TrialStat's original pricing program will continue to be available to organizations running small to mid-sized trials for which the model has now been optimized.

"We recognize that a one size fits all pricing model does not work well across the broad spectrum of clinical studies. Our original model was designed to be optimal for organizations running phase one, two and smaller phase three trials. As our volume of post marketing studies and large phase threes has increased, we felt that a new pricing scheme optimized for those types of studies was required. Our new pricing options give our clients increased flexibility to use a model that best suits their study type, size, duration and level of risk," said Jonathan Barker, President and CEO, TrialStat. "Ultimately, these new options further increase the value of our ClinicalAnalytics 4.0 platform for our customers."

"What I love about this new model is that my team is able to provide our CRO and sponsor customers with licensing quotations even more quickly and easily than before. Using basic data points like phase, number of sites and duration of study we can meet our customers' needs for rapid quote response," said Scott Morin, Vice President Sales, TrialStat. "One of our core values has always been industry leading project deployments and we can now augment this with equally timely proposals."

ClinicalAnalytics (CA) 4.0, TrialStat's on demand EDC solution, enables clinical research professionals to collect and manage study data nearly twice as fast as the industry average using innovative easy-to-use configurable and flexible features through a secure browser interface. CA 4.0 is the first EDC platform to allow all aspects of a study to be configured, deployed and managed through a browser interface, which enables customers to start their studies quickly and cost-effectively with no infrastructure investment.

TrialStat Corporation provides innovative clinical data solutions on demand that optimize the collection and management of research to enable customers to accelerate the commercialization of new life science products. CA 4.0 is a robust and scalable Web-based EDC on demand platform used by leading CROs and biopharma organizations. SRS 4.0® automates systematic reviews using real-time collaboration and management tools, while ESRNexus™ ( is the most comprehensive and free Web-based search engine for evidence-based reference literature. More information about TrialStat is available at

ClinicalAnalytics 4.0 and ESRNexus are registered trademarks of TrialStat Corporation.
SRS 4.0 is a trademark of TrialStat Corporation.

For media inquiries, please contact:
Muay Lim
TrialStat Corporation
613-741-9909 ext 153


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Muay Lim

1-617747-1000 814
Email >